Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Journal: Journal for immunotherapy of cancer
Published: July 21, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 10, 2025
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Journal: Journal for immunotherapy of cancer
Published: May 06, 2025
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.
Journal: Journal for immunotherapy of cancer
Published: December 12, 2024
The Clinical TIL Experience in Melanoma: Past, Present, Future.
Journal: Transplantation and cellular therapy
Published: November 15, 2024
Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults.
Journal: JAMA network open
Published: August 30, 2024
Proceedings of the seventh annual Women in Melanoma Conference.
Journal: Therapeutic advances in medical oncology
Published: July 22, 2024
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 22, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Journal: Journal for immunotherapy of cancer
Published: February 08, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Journal: Journal for immunotherapy of cancer
Published: February 05, 2024
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab.
Journal: Pigment cell & melanoma research
Published: January 12, 2024
Last Updated: 09/26/2026